Acalabrutinib vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. Clin. Oncol 2020 May 27;[EPub Ahead of Print], P Ghia, A Pluta, M Wach, D Lysak, T Kozak, M Simkovic, P Kaplan, I Kraychok, A Illes, J de la Serna, S Dolan, P Campbell, G Musuraca, A Jacob, E Avery, JH Lee, W Liang, P Patel, C Quah, W JurczakFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.